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Abstract
Therapeutic plasma exchange (TPE) is a potentially life-saving procedure which effectively removes donor-specific
human leukocyte antigen (HLA) antibodies from the bloodstream, allowing critically ill heart transplant recipients to
receive a donor organ with less wait time, and reducing the risk of acute organ rejection. The bulk of coagulation
factors is initially removed from the blood during TPE using albumin and is later replaced with allogeneic plasma.
Coagulopathy may develop during TPE and then can persist due to intraoperative blood loss and hemodilution
during surgery and cardiopulmonary bypass. We hereby describe the utility of rotational thromboelastometry to
assess rapid coagulation changes during TPE and subsequent heart transplant (HT) surgery.
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Background
Therapeutic plasma exchange (TPE) is a procedure that
is used to remove potentially harmful antibodies and
toxins from a patient. It is indicated for many disease
conditions including autoimmune anemia, autoimmune
vasculitis, hemolytic uremic syndrome, and multiple
sclerosis [1]. TPE has been used in perioperative cardiac
surgical patients with antibodies relating to heparin-
induced thrombocytopenia [2], ABO incompatibility [3],
and donor-specific human leukocyte antigen (HLA) [4].
The latter antibodies (ABO and HLA) are pertinent to
organ donor matching, and transplant recipients may
suffer from long waits for organs due to incompatible
antibodies. Perioperative removal of these antibodies via
TPE is feasible and often life-saving for critically ill
organ recipients.
Albumin (5 %) is useful as an exchange fluid for serial
TPEs because of potential risks associated with a large
amount of fresh frozen plasma (hereinafter referred to
as plasma) [5]. In particular, allergic reactions can occur
in up to 40–65 % of patients undergoing multiple TPEs,
although the severity of symptoms may vary [5–7]. It is
thus routine at our institution to perform two plasma
volume exchanges using 5 % albumin, followed by an-
other TPE with plasma. The loss of coagulation factors
during TPE is expected [8], but there is no strong evi-
dence to support the superiority of plasma-only TPE
over albumin/plasma combination for non-surgical
TPE indications [5, 9]. Perioperative TPEs using albu-
min/plasma raise concerns about coagulation status be-
cause a single TPE with plasma may be insufficient to
fully restore hemostatic factor levels before the use of
cardiopulmonary bypass (CPB). Rotational thromboe-
lastometry (TEM Innovations, Munich) was thus used
to assess rapid coagulation changes during repeat TPEs
in this case of a patient with donor-specific HLA anti-
bodies who underwent a heart transplantation. The aim
of this report is to address the clinical implications of
TPE on coagulation and hemodynamic management in
the transplant recipient.
Case presentation
A 43-year-old female, 66 kg, with non-ischemic cardio-
myopathy (NICM) presented for HT. She was diagnosed
with NICM 15 years ago, presumably related to preg-
nancy and/or systemic lupus erythematous (SLE). Her
past medical history included SLE with associated neph-
ritis and vasculitis, insulin-dependent diabetes mellitus,
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previous pulmonary embolism, and previous stroke with
residual visual field defects.
The patient had been stable on a biventricular assist
device (BiVAD; HeartWare, Framingham, MA, USA) for
2 years while no HLA-matched donor was found despite
a 1b (moderate urgency) status. She was recently hos-
pitalized for worsening right heart function and was
requiring increased inotropic support. Given the decline
in her clinical condition, the transplant team decided to
use therapeutic plasma exchange (TPE), anti-lymphocyte
antibody treatment, and intravenous immunoglobulin
treatment in the perioperative period in order to accept
a cross-match positive donor heart [4, 10].
After an uneventful induction of anesthesia and line
placement, a large dual lumen catheter was placed in the
femoral vein and connected to the plasmapheresis device
(Prismaflex® System, GAMBRO, Colorado). She under-
went TPEs consisting of three plasma volume exchanges;
the first two exchanges used 5 % albumin (3300 ml each)
to remove the HLA antibodies. The third plasma ex-
change utilized 11 units of FFP to restore coagulation
factors for surgery. Throughout the procedure, coagula-
tion status was assessed using tissue factor-activated
EXTEM and FIBTEM on rotational thromboelastometry
(Fig. 1). Baseline (pre-TPE) EXTEM and FIBTEM pa-
rameters were within normal range except for a high
FIBTEM-A10. After TPE with albumin, EXTEM-CT in-
creased from 55 to 74 s. FIBTEM-A10 decreased from 34
to 9 mm (−64.0 %) (Fig. 1a, b). TPE continued with FFP
(~35 ml/kg) during the explantation of the BiVAD device,
and FIBTEM-A10 was 7 mm at the conclusion of this third
round of TPE (Fig. 1c). Measured plasma fibrinogen
levels, which were reported approximately 25–45 min
after FIBTEM-A10 results were available, confirmed a net
loss of fibrinogen (Fig. 1a, c).
The donor heart was implanted over 192 min of CPB
with a cross-clamp time of 93 min and a donor ischemic
time of 256 min. After transplant and reperfusion, the
patient was initially weaned from CPB with inotropic
support (epinephrine 0.06 μg/kg/min and norepinephrine
0.03 μg/kg/min). Diffuse microvascular bleeding was at-
tributed to thrombocytopenia (EXTEM-A10, 31 mm) and
low fibrinogen (FIBTEM-A10, 7 mm) (Fig. 1c). One pool
of five single donor platelets and 20 units (four pools) of
cryoprecipitate were transfused, and improved hemostasis
was observed in the surgical field in conjunction with nor-
malized EXTEM and FIBTEM A10 values (Fig. 1d).
In the post-CPB period, systolic dysfunction persisted
on increasing doses of epinephrine and norepinephrine
(up to 0.1 μg/kg/min) despite adding vasopressin
(0.06 units/min) and milrinone (0.375 μg/kg/min).
Levothyroxine (T4; 20 μg/kg bolus, followed by 5 μg/
kg/h infusion) was added to treat “stunned” myocar-
dium due to the long ischemic time as well as the
potential for “euthyroid sick syndrome” exacerbated by
TPE [11, 12].
The transplant heart’s systolic function improved with
the T4 infusion, and further mechanical support (e.g.,
veno-arterial extracorporeal membrane oxygenation)
was avoided. The patient remained stable in the intensive
care unit (ICU), and the T4 infusion was weaned off along
with other inotropes on postoperative day (POD) 2. In the
ICU, four more sessions of TPE were performed to sustain
the eradication of donor-specific antibodies; one plasma
volume exchange with FFP on POD 1 and 2, and one
plasma volume exchanged with 5 % albumin on POD 3
and 5 (plasma fibrinogen levels were above 150 mg/dL
after TPEs). The patient was extubated on POD 5 and
discharged from the hospital on POD 14.
Discussion
Rotational thromboelastometry is a practical method to
assess rapid coagulation changes during surgery and
CPB, and in this case report, it was used successfully
during multiple TPEs for heart transplantation (HT).
[13]. Tissue factor-activated tests, EXTEM and FIBTEM
(Table 1), are most useful in the acute setting because
extrinsic coagulation factors and fibrinogen, respectively,
are particularly prone to hemodilution and blood
(plasma) losses [14, 15]. Clotting time (CT) of EXTEM
reflects prothrombin time (PT) sensitive coagulation fac-
tor levels [15], whereas 10 min amplitude (A10 clot firm-
ness) reflects platelet count and fibrinogen level [16].
FIBTEM better reflects plasma fibrinogen levels than
EXTEM because its clot formation is fibrin specific due
to the inclusion of cytochalasin D, a platelet inhibitor, in
the reagent [16, 17].
TPE is an important intervention for a variety of dis-
eases that require the removal of undesirable toxins or
antibodies. TPE potentially expands the donor pool for
heart and lung transplants which otherwise can be lim-
ited by recipient antibodies to donor HLA. One to one
and a half plasma volume runs of TPE generally remove
63–78 % of alloantibodies (mostly IgG class), and three
TPEs can reduce these antibodies by 90 % [18]. In con-
junction with immunosuppressive agents, TPE can sig-
nificantly reduce the risk of both acute and chronic
allograft organ rejection [4]. Reduced FIBTEM values
correlate with the substantial removal of large plasma
proteins (IgG, 150 kDa, and fibrinogen, 340 kDa) at the
end of albumin TPE [8]. Loss of fibrinogen and other
coagulation proteins during albumin TPE increase the
risk of bleeding, particularly after CPB, and thus allo-
geneic plasma is generally recommended for intraoper-
ative TPEs [2]. However, full recovery of fibrinogen is
unlikely even if plasma-only TPE is used [5, 9], and
CPB-induced hemodilution further decreases plasma fi-
brinogen [17]. Post-CPB fibrinogen levels below 200 mg/dL
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Fig. 1 a Key parameters of EXTEM-CT: clotting time (s) [normal, 43–82 s], EXTEM-A10: 10 min amplitude (mm) [normal, 43–65 mm], and FIBTEM-A10
[normal, 9–24 mm]. b–d EXTEM and FIBTEM changes during and after therapeutic plasma exchange (TPE). Baseline fibrinogen was in supra-normal
range (b), but it extensively decreased after TPE with albumin (c) and even after plasma replacement during surgery. Fibrinogen was restored only after
the transfusion of cryoprecipitate (d)
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(FIBTEM-A10 < 10 mm) are associated with an in-
creased risk of bleeding and higher transfusion require-
ment [19, 20], and the restoration of fibrinogen to
>250 mg/dL (FIBTEM-A10 > 15-18 mm) appears to reduce
such risks [21]. We initially calculated the required
amount (g) of fibrinogen using the published formula
below based on the FIBTEM-A10 value [21–23]:
Fibrinogen gð Þ ¼ target FIBTEM‐A10 mmð Þ – current FIBTEM‐A10 mmð Þ½ 
 weight kgð Þ  140 ¼ 15 mm – 7 mmð Þ
 66 kg 140 ¼ 3:77 g
In the USA, clinical use of fibrinogen concentrate is
limited to hereditary afibrinogenemia and hypofibrino-
genemia [24], and thus cryoprecipitate remains the
mainstay therapy for perioperative fibrinogen replace-
ment. The required amount (units) of cryoprecipitate
can be estimated by multiplying the fibrinogen dose by
five [25]; 3.77 × 5 = 18.9 units.
After transfusing 20 units of cryoprecipitate, FIBTEM-
A10 and fibrinogen were 16 mm and 276 mg/dL,
respectively.
Our case demonstrates the practical use of EXTEM
and FIBTEM in monitoring perioperative changes in fi-
brinogen levels and the therapeutic effects of cryopre-
cipitate (Fig. 1c, d) during TPE. It is also important to
note that antibiotics (ceftazidime, tobramycin, etc.) and
immunosuppressants (basiliximab) can also be elimi-
nated by TPE [26, 27].
In addition, TPE is known to affect biologically active
hormones, including free thyroxine (T4) and triiodothyr-
onine (T3) [12]. Critically ill patients have limited re-
serves of thyroid hormones [11], and there is some
evidence to suggest that there is better preservation and
function of the donor heart using T3 or T4 infusion [28].
Therefore, T4 infusion may be potentially useful for the
management of stunned donor heart.
Conclusions
In conclusion, the use of TPE expands the donor organ
pool to patients who otherwise would have an either a
low probability of or a long wait before receiving a
donor organ. In these patients, thromboelastometry
throughout the perioperative period can allow for a fast
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